Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium vs Formoterol Fumarate in COPD
NCT02937584Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Dec 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GP MDI (PT001) with FF MDI (PT005) (2 arms). Primary endpoints: Specific Image-Based Airway Volume at Day 15 and Specific Image-based Airway Resistance at Day 15. Started Dec 2016; status: completed.
02
Drugs
glycopyrroniumformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02937584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937584.